Articles dans des revues avec comité de lecture (13)
  1. 1. Larcin, L., Karakaya, G., Rygaert, X., Van Wilder, P., Lamy, C., Demyttenaere, B., Damase-Michel, C., & Kirakoya, F. (2022). Trends and regional variations in prescriptions dispensed to stimulate uterine contractions at the end of pregnancy in Belgium: A community-based study from 2003 to 2018. Pharmacoepidemiology and drug safety. doi:10.1002/pds.5558
  2. 2. Vandenplas, Y., Barbier, L., Simoens, S., Van Wilder, P., Vulto, A. A., & Huys, I. (2022). Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Frontiers in Pharmacology, 12, 789640. doi:10.3389/fphar.2021.789640
  3. 3. Nuijten, M., & Van Wilder, P. (2021). The impact of early phase price agreements on prices of orphan drugs. BMC health services research, 21(1), 222. doi:10.1186/s12913-021-06208-7
  4. 4. Dehanne, F., Gourdin, M., Devleesschauwer, B., Bihin, B., Van Wilder, P., Mareschal, B., Leclercq, P., & Pirson, M. (2021). Cost-DALY comparison of hip replacement care in 12 Belgian hospitals. BMJ open quality, 10(3), 1-11. doi:10.1136/bmjoq-2020-001263
  5. 5. Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A. A., & Huys, I. (2021). Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis. Frontiers in Pharmacology, 12, 644187. doi:10.3389/fphar.2021.644187
  6. 6. Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A. A., & Huys, I. (2021). Informing patients about biosimilar medicines: The role of European patient associations. Pharmaceuticals, 14(2), 117, 1-21. doi:10.3390/ph14020117
  7. 7. Annemans, L., Beutels, P., Bloom, D. D., De Backer, W., Ethgen, O., Luyten, J., Van Wilder, P., Willem, L., & Simoens, S. (2020). Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective. Value in health. doi:10.1016/j.jval.2020.09.005
  8. 8. De Foor, J., Van Wilder, P., Leclercq, P., Martins, D., & Pirson, M. (2019). The hospital cost of hip replacement for old inpatients in Belgium. European Geriatric Medicine, 10(1), 67-78. doi:10.1007/s41999-018-0150-3
  9. 9. Dehanne, F., Leclercq, P., Van Wilder, P., Gourdin, M., & Pirson, M. (2019). Benchmarking of hip prosthesis in 7 hospitals. Journal de gestion et d'économie médicales, 37(5-6), 1-21.
  10. 10. Van Wilder, P., Pirson, M., & Dupont, A. (2019). Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium. European Journal of Clinical Pharmacology. doi:10.1007/s00228-019-02665-6
  11. 11. Odnoletkova, I., Kindle, G., Quinti, I., Grimbacher, B., Knerr, V., Gathmann, B., Ehl, S., Mahlaoui, N., Van Wilder, P., Bogaerts, K., & de Vries, E. (2018). The burden of common variable immunodeficiency disorders: a retrospective analysis of the European Society for Immunodeficiency (ESID) registry data. Orphanet journal of rare diseases, 13(1), 201. doi:10.1186/s13023-018-0941-0
  12. 12. Delo, C., Van Wilder, P., van den bulcke, J., Martins, D., Leclercq, P., & Pirson, M. (2018). Impact de la dépendance à l'alcool sur le coût et la durée des séjours hospitaliers. Journal de gestion et d'économie médicales, 36(4), 201-216.
    13. << Précédent 1 2 Suivant >>